Role of Toll-like receptor-driven innate immunity in thoracic organ transplantation

被引:26
作者
Goldstein, DR
Palmer, SM
机构
[1] Yale Univ, Sch Med, Sect Cardiovasc Med, New Haven, CT 06520 USA
[2] Duke Univ, Med Ctr, Dept Med, Div Pulm & Crit Care Med, Durham, NC USA
关键词
D O I
10.1016/j.healun.2005.01.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Innate immunity represents the first line of defense against microbial invasion. Recent studies have determined that a group of germline-encoded receptors, termed Toll-like receptors (TLRs), are critical for recognizing foreign motifs on microbial organisms and initiating innate responses. An exciting area of research has recently linked activation of TLRs on antigen-presenting cells (APCs) to effective antigen presentation and activation of naive T cells. Most studies have shown that TLR-dependent immune function leads to T-helper 1 (TH1) immunity, although evidence also supports that TH2. immune responses may be initiated by TLR signaling in certain contexts. In either case, innate immune signaling via TLRs leads to a productive adaptive immune response. In contrast to studies in purely infectious models, emerging data from experimental and clinical studies have provided evidence that TLR immune function is important in acute allograft rejection. Specifically, MyD88, an important TLR signal adaptor, was found to be critical for the rejection of minor-mismatched skin allografts, and important for alloimmune priming and TH1 immunity against fully allogeneic skin grafts. Furthermore, a clinical study has shown that recipients with TLR 4 polymorphisms associated with endotoxin hyporesponsiveness manifest reduce acute lung allograft rejection. Collectively, these studies demonstrate that innate immunity is important for alloimmunity. Future therapeutic modalities that target innate rather than adaptive immune mechanisms represent a promising avenue for future studies in thoracic organ transplantation.
引用
收藏
页码:1721 / 1729
页数:9
相关论文
共 79 条
[1]   Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections [J].
Agnese, DM ;
Calvano, JE ;
Hahm, SJ ;
Coyle, SM ;
Corbett, SA ;
Calvano, SE ;
Lowry, SF .
JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (10) :1522-1525
[2]   Mammalian Toll-like receptors [J].
Akira, S .
CURRENT OPINION IN IMMUNOLOGY, 2003, 15 (01) :5-11
[3]   TLR4 mutations are associated with endotoxin hyporesponsiveness in humans [J].
Arbour, NC ;
Lorenz, E ;
Schutte, BC ;
Zabner, J ;
Kline, JN ;
Jones, M ;
Frees, K ;
Watt, JL ;
Schwartz, DA .
NATURE GENETICS, 2000, 25 (02) :187-+
[4]   Novel signal transduction pathway utilized by extracellular HSP70 -: Role of Toll-like receptor (TLR) 2 AND TLR4 [J].
Asea, A ;
Rehli, M ;
Kabingu, E ;
Boch, JA ;
Baré, O ;
Auron, PE ;
Stevenson, MA ;
Calderwood, SK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (17) :15028-15034
[5]   HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine [J].
Asea, A ;
Kraeft, SK ;
Kurt-Jones, EA ;
Stevenson, MA ;
Chen, LB ;
Finberg, RW ;
Koo, GC ;
Calderwood, SK .
NATURE MEDICINE, 2000, 6 (04) :435-442
[6]   Toll-like receptor signaling pathways [J].
Barton, GM ;
Medzhitov, R .
SCIENCE, 2003, 300 (5625) :1524-1525
[7]   Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways [J].
Björkbacka, H ;
Kunjathoor, VV ;
Moore, KJ ;
Koehn, S ;
Ordija, CM ;
Lee, MA ;
Means, T ;
Halmen, K ;
Luster, AD ;
Golenbock, DT ;
Freeman, MW .
NATURE MEDICINE, 2004, 10 (04) :416-421
[8]   Dectin-1 mediates the biological effects of β-glucans [J].
Brown, GD ;
Herre, J ;
Williams, DL ;
Willment, JA ;
Marshall, ASJ ;
Gordon, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (09) :1119-1124
[9]   Inhibition of interleukin 1 receptor/toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4 [J].
Burns, K ;
Janssens, S ;
Brissoni, B ;
Olivos, N ;
Beyaert, R ;
Tschopp, J .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 197 (02) :263-268
[10]  
Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945